TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
A review in the Journal of the Endocrine Society says existing evidence suggests women with polyendocrine metabolic ovarian syndrome may have greater risk of memory and brain changes associated with Alzheimer’s disease and dementia. The authors say the association may be driven largely by conditions such as insulin resistance and obesity; the review does not establish that PMOS causes dementia.
A review of existing research reports a possible link between polyendocrine metabolic ovarian syndrome (PMOS) and Alzheimer’s disease and related dementias, but says the association may be connected to metabolic conditions such as insulin resistance and obesity rather than to PMOS itself. The paper, published in the Journal of the Endocrine Society, assesses prior evidence and does not establish that the syndrome causes dementia.
The researchers conducted a PubMed search from its inception through October 2025 and reviewed evidence on PMOS, brain health and Alzheimer’s disease and related dementias. They report that people with PMOS may face greater risk of changes affecting memory, thinking and brain health, and identify potential pathways shared with Alzheimer’s-related conditions. These are conclusions drawn from existing research, not results from a new clinical trial tracking participants over time.
The review describes mild but reproducible impairments in executive function and memory among patients with PMOS, alongside reported structural and functional brain alterations. The authors say these findings could point to increased vulnerability, but they do not show that every person with PMOS will develop cognitive problems or dementia.
PMOS was formerly known as polycystic ovary syndrome (PCOS). The source report says it affects an estimated 10% to 15% of women worldwide and is associated with health conditions including diabetes, heart disease, stroke, depression, anxiety, infertility and endometrial cancer. The review’s authors emphasize that metabolic comorbidities may help explain the observed connection with dementia-related outcomes.
Metabolic Health May Shape the Link
The findings raise a question with potential relevance to the long-term health of people with PMOS: whether the syndrome and its common metabolic complications are associated with changes in memory and brain health. Because the review points particularly to insulin resistance and obesity, clarifying their role could help researchers distinguish risks associated with PMOS from those associated with conditions that frequently occur alongside it.
That distinction matters for interpreting the evidence. The review does not show that PMOS independently increases dementia risk, nor does it identify a proven prevention or treatment strategy. Instead, it signals a possible relationship that warrants stronger study. The authors say examining shared pathways could help explain both conditions and inform future research into treatments, but no such treatment outcome is established by this review.
For readers with PMOS, the report should not be read as a prediction of an individual’s future health. It is a synthesis of research findings and proposed mechanisms, with important gaps still present. Anyone seeking advice about personal health risks or care should consult a qualified health professional.
insulin resistance management supplements
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
From PCOS to PMOS Research
The paper uses PMOS, a newer name for polycystic ovary syndrome, and examines possible relationships between the condition and Alzheimer’s disease and related dementias. According to the source report, PMOS can have lifelong effects and may affect males differently as well, although the review’s reported cognitive findings concern patients with PMOS and the headline focuses on women.
The authors reviewed publications rather than reporting a single new population study. Their analysis therefore brings together evidence from earlier work, including research on cognition, brain changes and metabolic conditions. The article was published in 2026, while the literature search ended in October 2025; evidence published after that cutoff was not part of the search described in the report.
The study was funded by the Foundation for Research and Education Excellence. Ricardo Azziz, a co-author affiliated with the University of Alabama at Birmingham, is quoted in the report discussing the possible relationship and the need for further investigation. Funding and author affiliations are relevant details for readers assessing the publication, but the provided material does not report an independent replication of its conclusions.
““Current evidence suggests that any association between PMOS and Alzheimer’s disease and dementia is likely mediated by metabolic comorbidities, particularly insulin resistance and obesity, rather than an independent effect of PMOS itself.””
— Ricardo Azziz, study co-author and University of Alabama at Birmingham researcher
Causation and Individual Risk Remain Unknown
The review does not establish whether PMOS causes Alzheimer’s disease or dementia, whether metabolic conditions account for all or only part of the association, or how large any added risk might be. The source material provides no risk estimate, study population size, or evidence of a causal effect. It also does not specify how findings may differ by age, PMOS features, duration of illness or other health factors.
The authors describe gaps in the evidence and call for future research. Since the analysis is based on studies available through October 2025, it also cannot include later findings. The reported cognitive and brain changes are not equivalent to a diagnosis of Alzheimer’s disease or dementia, and the material does not show that these changes progress to either condition.
Research Needed to Test the Association
The authors identify further research as necessary to clarify how PMOS, metabolic comorbidities and dementia-related pathways may be connected. Future studies would need to distinguish the effects of PMOS from those of conditions such as obesity and insulin resistance and determine whether the reported cognitive findings predict later dementia. The source report does not announce a specific follow-up study or timeline.
For now, the review adds a possible association to the research agenda rather than changing clinical guidance. Any personal questions about PMOS, cognitive symptoms or dementia risk should be discussed with a qualified health professional; the study is not medical advice.
Key Questions
What is PMOS?
Polyendocrine metabolic ovarian syndrome (PMOS) is the name used in the review for a condition formerly known as polycystic ovary syndrome, or PCOS.
Does the review prove PMOS causes Alzheimer’s disease?
No. It reviews existing evidence and reports a possible association. The authors say it may be mediated by metabolic conditions such as insulin resistance and obesity, rather than by PMOS independently.
What brain or cognitive findings did the review describe?
The review reports mild, reproducible impairments in executive function and memory, as well as structural and functional brain alterations in patients with PMOS. These findings do not by themselves establish a dementia diagnosis or show that dementia will develop.
How current was the research reviewed?
The researchers searched PubMed from its inception through October 2025. Studies published after that cutoff were not included in the search described in the source report.
What should people with PMOS do with these findings?
The review is not a personal risk assessment or medical advice. People with questions about their health or cognitive symptoms should consult a qualified health professional.
Source: rss
Cold & flu season Picks
humidifiers
As an affiliate, we earn on qualifying purchases.
